Beam Therapeutics (BEAM) Equity Income (2020 - 2026)
Beam Therapeutics (BEAM) reported Equity Income of $16000.0 for Q1 2026, up 100.77% year-over-year from $7969.4 in Q1 2025, and up 100.48% on a QoQ basis from -$3.3 million in Q4 2025.
Beam Therapeutics (BEAM) has 7 years of Equity Income data on file, last reported at $16000.0 in Q1 2026.
- Quarterly Equity Income rose 100.77% year-over-year to $16000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (up 147.1% YoY) and the FY2025 annual result came in at $3.9 million, up 127.97% from the prior year.
- Equity Income advanced to $16000.0 in Q1 2026 per BEAM's latest filing, from -$3.3 million in the prior quarter.
- Across five years, Equity Income topped out at $45.7 million in Q4 2022 and bottomed at -$12.8 million in Q1 2023.
- The 5-year median for Equity Income is -$2.1 million (2024), against an average of $917352.9.
- Peak annual rise in Equity Income reached 1170.26% in 2022, while the deepest fall reached 839.65% in 2022.
- Tracing BEAM's Equity Income over 5 years: stood at $45.7 million in 2022, then tumbled by 101.58% to -$722000.0 in 2023, then plunged by 50.97% to -$1.1 million in 2024, then plunged by 205.41% to -$3.3 million in 2025, then soared by 100.48% to $16000.0 in 2026.
- Per Business Quant, the three latest BEAM Equity Income figures stand at $16000.0 (Q1 2026), -$3.3 million (Q4 2025), and $4.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Beam Therapeutics | 3.40 Bn | 3.40 Bn | - | 16,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16,000.00 |
| Dec 31, 2025 | -3.33 Mn |
| Sep 30, 2025 | 4.94 Mn |
| Jun 30, 2025 | 4.42 Mn |
| Mar 31, 2025 | -2.08 Mn |
| Dec 31, 2024 | -1.09 Mn |
| Sep 30, 2024 | -2.06 Mn |
| Jun 30, 2024 | -7.59 Mn |
| Mar 31, 2024 | -3.35 Mn |
| Dec 31, 2023 | -722,000.00 |
| Sep 30, 2023 | -11.22 Mn |
| Jun 30, 2023 | 6.15 Mn |
| Mar 31, 2023 | -12.80 Mn |
| Dec 31, 2022 | 45.70 Mn |
| Sep 30, 2022 | 10.43 Mn |
| Jun 30, 2022 | -4.12 Mn |
| Mar 31, 2022 | -7.69 Mn |
| Dec 31, 2021 | -4.27 Mn |
| Sep 30, 2021 | -4.89 Mn |
| Jun 30, 2021 | 25.81 Mn |
| Mar 31, 2021 | 1.04 Mn |
| Jun 30, 2020 | 517,000.00 |